GW Pharmaceuticals plc

https://www.gwpharm.com

GW Pharmaceuticals plc (AIM:GWP) was founded in 1998 and is listed on the AiM, a market of the London Stock Exchange. Operating under licence from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular MS and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. *

	Start	1998-01-01 established
	Industry	pharmaceutical
	Industry 2	Epidiolex®
	Person	Gover, Justin (GW Pharmaceuticals 202102 CEO)

	Region	Salisbury, Wiltshire
	Country	United Kingdom (GB)
	Street	Porton Down Science Park
	City	SP4 0JQ Salisbury
	Tel	+44-1980-557000
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2006-09-30)
	Currency	GBP
	Annual sales	1,981,000 (turnover (2005/06) 2006-09-30)
	Profit	11,915,000 (2006-09-30)
	Cash	19,900,000 (2006-09-30)

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for GW Pharmaceuticals plc

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)